Dec 17, 2019: Roche and Spark Therapeutics, Inc. announced the completion of the acquisition following the receipt of regulatory approval from all the government authorities required by the merger agreement.
Roche and Spark together will be able to appreciably improve the lives of patients through innovative gene therapies.Â
This acquisition supports our long-lasting commitment in order to bring transformational therapies and innovative approaches to people around the world with serious diseases.
Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully incorporated, commercial company that is committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, haemophilia, lysosomal storage disorders and neurodegenerative diseases, also Spark Therapeutics will continue to operate as an independent company within the Roche Group. https://www.roche.com/media/releases/med-cor-2019-12-17b.htm
